Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

Stifel has downgraded Tempus AI (NASDAQ:TEM) to hold from buy, citing valuation and uncertainty about core growth in 2025.

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

Stifel Nicolaus analyst Daniel Arias downgraded the rating on Tempus AI, Inc. Class A (TEM – Research Report) to a Hold yesterday, ...

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit.

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Thank you for standing by. My name is Briana, and I will be your conference operator today. At this time, I’d like to welcome everyone to ...

Tempus announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing. Under the terms of the ...

Tempus AI said it agreed to pay $375 million in cash and $225 million in shares to acquire genetic testing company Ambry Genetics. Ambry conducts hereditary cancer screening and currently serves as ...

Aliso Viejo-based Ambrey Genetics Corp., Orange County’s third-largest medical diagnostics and testing company, has entered ...

The Groupon co-founder and tech billionaire will be tasked with leading the Art Institute as it embarks on construction of a ...

IPS test validation study data will be unveiled at the 2024 SITC Annual Meeting CHICAGO, November 07, 2024--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the ...